PURPOSE: Invasive non-functional pituitary adenomas (NFPAs) constitute 35% of NFPAs. Despite a relatively large body of molecular investigations on the invasiveness of NFPA, the underlying molecular mechanisms of invasiveness are yet to be determined. Herein, we aimed to provide an overview of gene/microRNA(miRNAs) expression alterations in invasive NFPA. METHODS: This article describes a systematic literature review of articles published up to March 23, 2021, on the transcriptional alterations of invasive NFPA. Five digital libraries were searched, and 42 articles in total fulfilled the eligibility criteria. Pathway enrichment was conducted, and protein interactions among the identified deregulated genes were inferred. RESULTS: In total 133 gene/protein transcriptional alterations, comprising 87 increased and 46 decreased expressions, were detected in a collective number of 1001 invasive compared with 1007 non-invasive patients with NFPA. Deregulation of CDH1, PTTG1, CCNB1, SNAI1, SLUG, EZR, and PRKACB, which are associated with epidermal-mesenchymal transition (EMT), was identified. Moreover, six members of the angiogenesis pathway, i.e., VEGFA, FLT1, CCND1, CTNNB1, MYC(c-MYC), and PTTG1, were detected. SLC2A1, FLT1, and VEGFA were also recognized in the hypoxia pathway. Physical interactions of CTNNB1 with FLT1, CCND1, and EZR as well as its indirect interactions with VEGFA, MYC, CCNB1, and PCNA indicate the tight interplay between EMT, angiogenesis, and hypoxia pathways in invasive NFPAs. In addition, Hippo, JAK-STAT, MAPK, Wnt, PI3K-Akt, Ras, TGF-b, VEGF, and ErbB were identified as interwoven signaling pathways. CONCLUSION: In conclusion, invasive NFPA shares very common deregulated signaling pathways with invasive cancers. A large amount of heterogeneity in the reported deregulations in different studies necessitates the validation of the expressional changes of the suggested biomarkers in a large number of patients with invasive NFPA.
PURPOSE: Invasive non-functional pituitary adenomas (NFPAs) constitute 35% of NFPAs. Despite a relatively large body of molecular investigations on the invasiveness of NFPA, the underlying molecular mechanisms of invasiveness are yet to be determined. Herein, we aimed to provide an overview of gene/microRNA(miRNAs) expression alterations in invasive NFPA. METHODS: This article describes a systematic literature review of articles published up to March 23, 2021, on the transcriptional alterations of invasive NFPA. Five digital libraries were searched, and 42 articles in total fulfilled the eligibility criteria. Pathway enrichment was conducted, and protein interactions among the identified deregulated genes were inferred. RESULTS: In total 133 gene/protein transcriptional alterations, comprising 87 increased and 46 decreased expressions, were detected in a collective number of 1001 invasive compared with 1007 non-invasive patients with NFPA. Deregulation of CDH1, PTTG1, CCNB1, SNAI1, SLUG, EZR, and PRKACB, which are associated with epidermal-mesenchymal transition (EMT), was identified. Moreover, six members of the angiogenesis pathway, i.e., VEGFA, FLT1, CCND1, CTNNB1, MYC(c-MYC), and PTTG1, were detected. SLC2A1, FLT1, and VEGFA were also recognized in the hypoxia pathway. Physical interactions of CTNNB1 with FLT1, CCND1, and EZR as well as its indirect interactions with VEGFA, MYC, CCNB1, and PCNA indicate the tight interplay between EMT, angiogenesis, and hypoxia pathways in invasive NFPAs. In addition, Hippo, JAK-STAT, MAPK, Wnt, PI3K-Akt, Ras, TGF-b, VEGF, and ErbB were identified as interwoven signaling pathways. CONCLUSION: In conclusion, invasive NFPA shares very common deregulated signaling pathways with invasive cancers. A large amount of heterogeneity in the reported deregulations in different studies necessitates the validation of the expressional changes of the suggested biomarkers in a large number of patients with invasive NFPA.
Authors: P D Delgado-López; J Pi-Barrio; M T Dueñas-Polo; M Pascual-Llorente; M C Gordón-Bolaños Journal: Clin Transl Oncol Date: 2018-04-05 Impact factor: 3.405
Authors: S Asioli; A Righi; M Iommi; C Baldovini; F Ambrosi; F Guaraldi; M Zoli; D Mazzatenta; M Faustini-Fustini; P Rucci; C Giannini; M P Foschini Journal: Eur J Endocrinol Date: 2019-02-01 Impact factor: 6.664
Authors: Jacqueline Trouillas; Pascal Roy; Nathalie Sturm; Emmanuelle Dantony; Christine Cortet-Rudelli; Gabriel Viennet; Jean-François Bonneville; Richard Assaker; Carole Auger; Thierry Brue; Aurélie Cornelius; Henry Dufour; Emmanuel Jouanneau; Patrick François; Françoise Galland; François Mougel; François Chapuis; Laurent Villeneuve; Claude-Alain Maurage; Dominique Figarella-Branger; Gérald Raverot; A Barlier; M Bernier; F Bonnet; F Borson-Chazot; G Brassier; S Caulet-Maugendre; O Chabre; P Chanson; J F Cottier; B Delemer; E Delgrange; L Di Tommaso; S Eimer; S Gaillard; M Jan; J J Girard; V Lapras; H Loiseau; J G Passagia; M Patey; A Penfornis; J Y Poirier; G Perrin; A Tabarin Journal: Acta Neuropathol Date: 2013-02-12 Impact factor: 17.088
Authors: Jelena Maletkovic; Asmaa Dabbagh; Dongyun Zhang; Abdul Zahid; Marvin Bergsneider; Marilene B Wang; Michael Linetsky; Noriko Salamon; William H Yong; Harry V Vinters; Anthony P Heaney Journal: J Endocr Soc Date: 2019-07-23
Authors: Pamela U Freda; Jeffrey N Bruce; Alexander G Khandji; Zhezhen Jin; Richard A Hickman; Emily Frey; Carlos Reyes-Vidal; Marc Otten; Sharon L Wardlaw; Kalmon D Post Journal: J Endocr Soc Date: 2020-02-18